نتایج جستجو برای: avonex

تعداد نتایج: 115  

Journal: :Journal of neurology, neurosurgery, and psychiatry 2003
B D Dubois E Keenan B E Porter R Kapoor P Rudge A J Thompson D H Miller G Giovannoni

BACKGROUND The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting multiple sclerosis (MS). However, the use of this drug in clinical practice is complex, especially because it is only partially effective, its long term efficacy and side effects are unknown, its efficacy may be abrogated by the development of neutralising antibodies, compliance is variable, and its...

Journal: :acta medica iranica 0
keivan basiri neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. masood etemadifar neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. fatemeh derakhshan neuroscience research center, isfahan university of medical sciences, isfahan, iran. fereshteh ashtari neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. vahid shaygannejad neuroscience research center, isfahan university of medical sciences, isfahan, iran. and department of neurology, isfahan university of medical sciences, isfahan, iran. zahra fatehi neuroscience research center, isfahan university of medical sciences, isfahan, iran.

none of the approved immunomodulatory drugs in adults multiple sclerosis (ms) patients have been officially approved for the pediatric patients and are currently used off-label in this population. in this study, we evaluated the effectiveness and tolerability of intramuscular interferon beta1-a (avonex®) and subcutaneously injected interferon beta1-b (betaferon®) in children with definite relap...

Ali Reza Rezaei Ashtiani, Babak Zamani, Mohammad Rohani,

Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...

Journal: :Archives of neurology 2001
J A Cohen G R Cutter J S Fischer A D Goodman F R Heidenreich A J Jak J E Kniker M F Kooijmans J M Lull A W Sandrock J H Simon N A Simonian J N Whitaker

BACKGROUND The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The MSFC is the primary outcome measure in the ongoing multinational phase 3 trial of interferon beta-1a (Avonex...

2012
J. Nicholas B. Morgan-Followell D. Pitt M.K. Racke A. Boster

The therapeutic landscape for multiple sclerosis (MS) is rapidly changing. Currently, there are eight FDA approved disease modifying therapies for MS including: IFN-β-1a (Avonex, Rebif), IFN-β-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), and fingolimod (Gilenya). This review will highlight the experience to date and key clinical trial...

Journal: :Folia neuropathologica 2004
Adam Szczuciński Jacek Losy

Chemokines play an important role in pathogenesis of multiple sclerosis (MS), mediating migration of leukocytes into the central nervous system. CCL2 (MCP-1) chemokine is expressed in astrocytes in MS lesions. The aim of the study was to evaluate the effect of a two-year treatment with IFN-beta 1a on serum CCL2 level in MS patients. CCL2 concentration in sera of 18 relapsing-remitting MS (RR-MS...

Journal: :BMJ case reports 2014
Aldrin Anthony Dung Dung Akhila Kumar Panda

On the basis of evidence from clinical trials, contraindications to the use of interferon (INF) are pregnancy, epilepsy and depression. Management of multiple sclerosis during pregnancy is a difficult issue because of pregnancy-related complications and fear of congenital anomalies due to exposure to disease-modifying therapy. In different series, INF therapy was withdrawn before or after varia...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید